Title:Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer
Volume: 18
Issue: 9
Author(s): Fengquan Chen, Chunxi Liu, Jian Zhang, Wenfang Xu*Yingjie Zhang*
Affiliation:
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji'nan, Shandong,China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji'nan, Shandong,China
Keywords:
Cyclin-Dependent Kinases (CDKs), palbociclib, monotherapy, combined therapy, anti-cancer, cell cycle arrest.
Abstract: The Cyclin-Dependent Kinases (CDKs) and their cyclin partners are key regulators of the cell cycle.
These kinases are closely related to oncogenesis and have been proved to be attractive targets for designing
novel anticancer agents. The CDK inhibitors can effectively suppress the excessive proliferation of tumor cells
by inducing cell cycle arrest. In recent years, a large number of CDK inhibitors have entered pre-clinical and/or
clinical trials. Among these compounds, the selective CDK4/6 inhibitor Palbociclib has been approved by FDA
for breast cancer treatment. Moreover, Palbociclib demonstrated promising antitumor potential as monotherapy
or combined therapy in numerous clinical trials. Herein, we provide a brief review focused on the recent progress
of clinical studies about Palbociclib.
